leisure time -WSS

leisure time

author：leisure time 2025-09-10 05:00:35 - browse：63374

Vertex Pharmaceuticals Inc. building — Craig F. Walker/The Boston Globe

Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease.

The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

“The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

explore

WSS

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Walmart eyes Medicare Advantage provider ChenMed

Venture capitalist Bob Kocher on the state of digital health

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Diverse clinical trials: Why aren’t we there yet?

entertainment

leisure time

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Cytokinetics CEO stresses company can launch heart drug on its own

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

How housing is health care on Long Island

How one medical school became remarkably diverse

Diverse clinical trials: Why aren’t we there yet?

In age of alternative facts, a scholarly course on calling out crap

Criminal prosecution for violating HIPAA: an emerging threat

Novavax promises a turnaround & Lilly roils the obesity market

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

hotspot

Food makers to regulators: Ultra

Private equity could exacerbate cardiology's overuse problem, experts fear

Popular nasal decongestant doesn't actually relieve congestion

What to make of Biden’s latest efforts on cancer research

WATCH: Why do bright lights make us see spots?

Hospitals consider fixing cancer drug shortages on their own

hotspot

focus

explore

knowledge